Overview

Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients

Status:
Recruiting

Trial end date:
2026-11-23

Target enrollment:

Participant gender:

Summary

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in Japanese osteoporosis patients after 2-year-denosumab therapy: SERM and eldecalcitol treatment for 24 months Bisphosphonates and eldecalcitol treatment for 24 months Eldecalcitol treatment for 24 months

Phase:

Phase 2

Details

Lead Sponsor:

Shinshu University

Treatments:

Denosumab
Diphosphonates